Novavax to Participate in Evercore ISI's 4th Annual HealthCONx Virtual Conference
Novavax, a biotechnology company focused on next-generation vaccines, will participate in Evercore ISI's 4th Annual HealthCONx Virtual Conference on December 2, 2021, from 9:15 to 9:35 a.m. ET. The discussion will center on NVX-CoV2373, their protein-based COVID-19 vaccine. Participants include Gregory M. Glenn, M.D., and John J. Trizzino. Investors can access a replay of the fireside chat on Novavax's website for 90 days post-event. Novavax is advancing global health through innovative vaccines and has received Emergency Use Authorization for NVX-CoV2373 in Indonesia and the Philippines.
- None.
- None.
GAITHERSBURG, Md., Nov. 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in Evercore ISI's 4th Annual HealthCONx Virtual Conference. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.
Conference Details: Fireside Chat | |||
Date: | Thursday, December 2, 2021 | ||
Time: | 9:15 – 9:35 a.m. Eastern Time (ET) | ||
Moderator: | Josh Schimmer | ||
Novavax participants: | Gregory M. Glenn, M.D., President, Research and Development and John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer | ||
Conference | |||
Event: | Investor meetings | ||
Date: | Thursday, December 2, 2021 | ||
A replay of the recorded fireside session will be available through the events page of the Company's website at ir.novavax.com for 90 days.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company's COVID-19 vaccine, received Emergency Use Authorization in Indonesia and the Philippines and has been submitted for regulatory authorization in multiple markets globally. NanoFlu™, the company's quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Novavax is currently evaluating a COVID-NanoFluTM combination vaccine in a Phase 1/2 clinical trial, which combines the company's NVX-CoV2373 and NanoFluTM vaccine candidates. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Contacts:
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com
Solebury Trout
Alexandra Roy | 617-221-9197
aroy@soleburytrout.com
Media
Alison Chartan | 240-720-7804
Laura Keenan Lindsey | 202-709-7521
media@novavax.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-evercore-isis-4th-annual-healthconx-virtual-conference-301430525.html
SOURCE Novavax, Inc.
FAQ
What is the date of Novavax's participation in the HealthCONx Conference?
What time will Novavax's session at the HealthCONx Conference occur?
Who are the main participants from Novavax at the HealthCONx Conference?
What will Novavax discuss at the HealthCONx Conference?
Where can I watch the replay of Novavax's conference session?
What is the significance of NVX-CoV2373?
